AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31044424 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (100 μg)
Number of subjects: 90
Study 31044424 — intervention group
Group type: COMPARATOR
Intervention: Noradrenaline (5 μg)
Number of subjects: 90
Study 28011388 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching intervention for 6 months
Number of subjects: 0
Study 28011388 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care single dietary consultation
Number of subjects: 0
Study 26951588 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐consultation
Number of subjects: 36
Study 26951588 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional referrals)
Number of subjects: 36
Study 25197807 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 10 mg, 20 mg, 40 mg, 80 mg
Number of subjects: 353
Study 25197807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study 25197807 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg, Zolpidem 10 mg, Trazodone 150 mg
Number of subjects: 353
Study 21868715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg twice daily on days 1 to 3 and once on day 4
Number of subjects: 23
Study 21868715 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin loading dose of 0.5 mg on day 1 and 0.25 mg on days 2 to 4
Number of subjects: 23
Study 21868715 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate with digoxin on days 1 to 4
Number of subjects: 23
Study 19169664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 26
Study 19169664 — intervention group
Group type: COMPARATOR
Intervention: Nutritional therapy
Number of subjects: 26
Study 17253134 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalazine 1.6 g/d (group A)
Number of subjects: 40
Study 17253134 — intervention group
Group type: EXPERIMENTAL
Intervention: mesalazine 1.6 g/d 10 days per month (group B)
Number of subjects: 40
Study 17283930 — intervention group
Group type: EXPERIMENTAL
Intervention: Observers at the centre of projection
Number of subjects: 0
Study 17283930 — intervention group
Group type: COMPARATOR
Intervention: Observers at other viewpoints
Number of subjects: 0
Study 17283930 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of perspective cues
Number of subjects: 0
Study 14511961 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 191
Study 14511961 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 191
Study 10965287 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation treatment (Cognitive Therapy or Phenelzine)
Number of subjects: 31
Study 10965287 — intervention group
Group type: COMPARATOR
Intervention: Discontinued treatment (Pill placebo)
Number of subjects: 31
Study 8641739 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (angiotensin II receptor antagonist)
Number of subjects: 20
Study 8641739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1378680 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2.10(6) KIU before incision, 2.10(6) KIU prior to bypass, and 5.10(5) KIU/hr for 5 hrs)
Number of subjects: 115
Study 1378680 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 115
Study 6744780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 24
Study 6744780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30827782 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraflex (sirolimus-eluting stent with biodegradable polymer coating and ultra-thin struts)
Number of subjects: 1435
Study 30827782 — intervention group
Group type: COMPARATOR
Intervention: Xience (everolimus-eluting stent with durable polymer coating)
Number of subjects: 1435
Study 30827782 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraflex
Number of subjects: 1435
Study 30827782 — intervention group
Group type: COMPARATOR
Intervention: Xience
Number of subjects: 1435
Study 29253607 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-case experimental designs (SCED)
Number of subjects: 3
Study 27378550 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (400 mg)
Number of subjects: 121
Study 27378550 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 121
Study 27378550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 23684733 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) training
Number of subjects: 0
Study 23684733 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha/Theta (A/T) neurofeedback training
Number of subjects: 0
Study 23684733 — intervention group
Group type: COMPARATOR
Intervention: Choreology instruction
Number of subjects: 0
Study 23684733 — intervention group
Group type: COMPARATOR
Intervention: No-training control group
Number of subjects: 0
Study 23022402 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q₁₀ (CoQ₁₀)
Number of subjects: 0
Study 23022402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21041592 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored after-school hip-hop, African, and step dance classes and a home/family-based intervention to reduce screen media use
Number of subjects: 261
Study 21041592 — intervention group
Group type: COMPARATOR
Intervention: Information-based health education
Number of subjects: 261
Study 18830043 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (injectable form)
Number of subjects: 0
Study 18830043 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin (nasal spray preparations)
Number of subjects: 0
Study 16047088 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Dates program
Number of subjects: 0
Study 11809642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid cream
Number of subjects: 184
Study 11809642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 10084441 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosage pulsed ultrasound (mean dosage 172.8 J)
Number of subjects: 48
Study 10084441 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage pulsed ultrasound (mean dosage 345.6 J)
Number of subjects: 48
Study 10084441 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham insonation)
Number of subjects: 48
Study 10084441 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 7597425 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 and doxorubicin 75 mg/m2 every 3 weeks
Number of subjects: 12
Study 7597425 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m2 followed by paclitaxel 150 mg/m2
Number of subjects: 12
Study 7597425 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin as an intravenous push and paclitaxel as a 24-hour continuous infusion
Number of subjects: 12
Study 7597425 — intervention group
Group type: COMPARATOR
Intervention: Combination of doxorubicin and paclitaxel
Number of subjects: 12
Study 1975200 — intervention group
Group type: EXPERIMENTAL
Intervention: mequitazine 5 mg bd
Number of subjects: 59
Study 1975200 — intervention group
Group type: COMPARATOR
Intervention: terfenadine 60 mg bd
Number of subjects: 59
Study 7443111 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17 alpha-OHP-C)
Number of subjects: 77
Study 7443111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 31829925 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of atorvastatin (20 mg)
Number of subjects: 0
Study 31829925 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of atorvastatin (20 mg)
Number of subjects: 0
Study 29205675 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric disorder present
Number of subjects: 245
Study 29205675 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress
Number of subjects: 245
Study 28551374 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group intervention (n = 39)
Number of subjects: 117
Study 28551374 — intervention group
Group type: COMPARATOR
Intervention: Conventional postsurgical visits (Control group, n = 35)
Number of subjects: 117
Study 25107836 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients undergoing laparoscopic appendectomy
Number of subjects: 0
Study 25107836 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 0
Study 25107836 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 0
Study 24022431 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate laparoscopic surgery within 24 hours of hospital admission (group ILC)
Number of subjects: 618
Study 24022431 — intervention group
Group type: COMPARATOR
Intervention: Initial antibiotic treatment followed by delayed laparoscopic cholecystectomy at days 7 to 45 (group DLC)
Number of subjects: 618
Study 21418794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia postconditioning
Number of subjects: 64
Study 18192924 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting during Ramadan (35 patients)
Number of subjects: 68
Study 18192924 — intervention group
Group type: COMPARATOR
Intervention: Non-fasting during Ramadan (33 patients)
Number of subjects: 68
Study 16891381 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (228±93 mg/day) for at least 2 weeks prior to cardioversion
Number of subjects: 50
Study 16891381 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ARBs)
Number of subjects: 50
Study 12673783 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride + NPH insulin at bedtime
Number of subjects: 261
Study 12673783 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin twice daily
Number of subjects: 261
Study 12673783 — intervention group
Group type: COMPARATOR
Intervention: 30/70 mixture of short-acting and NPH insulin twice daily
Number of subjects: 261
Study 12673783 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 261
Study 10959995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracongruent polyethylene insert
Number of subjects: 100
Study 10959995 — intervention group
Group type: COMPARATOR
Intervention: PCL-sparing design
Number of subjects: 100
Study 9226461 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 5640
Study 9226461 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 5640
Study 1445500 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider referral
Number of subjects: 74
Study 1445500 — intervention group
Group type: COMPARATOR
Intervention: Patient referral
Number of subjects: 74
Study 1445500 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners notified by counselors
Number of subjects: 74
Study 1445500 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners notified and tested
Number of subjects: 74
Study 6141727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol alone
Number of subjects: 19
Study 6141727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol in combination with isosorbide dinitrate and nifedipine
Number of subjects: 19
Study 6141727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol and large doses of nifedipine
Number of subjects: 19
Study 6141727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol alone and in combination with isosorbide dinitrate
Number of subjects: 19
Study 6141727 — intervention group
Group type: EXPERIMENTAL
Intervention: All drug combinations
Number of subjects: 19
Study 30489496 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (40 min of uphill walking 4 d·wk at 70% heart rate reserve)
Number of subjects: 23
Study 30489496 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 23
Study 30489496 — intervention group
Group type: COMPARATOR
Intervention: Control (sedentary lifestyle)
Number of subjects: 23
Study 29894464 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Loading (IL)
Number of subjects: 133
Study 29894464 — intervention group
Group type: COMPARATOR
Intervention: Delayed Loading (DL)
Number of subjects: 133
Study 27054515 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 323
Study 27054515 — intervention group
Group type: EXPERIMENTAL
Intervention: Natamycin
Number of subjects: 323
Study 25536449 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies including screening and treatment of subclinical hypothyroidism
Number of subjects: 0
Study 25536449 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism
Number of subjects: 0
Study 23731684 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP titrated by stress index (15.1 ± 1.8 cmH2O)
Number of subjects: 30
Study 23731684 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP titrated by stress index
Number of subjects: 30
Study 23731684 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP titrated by stress index and oxygenation
Number of subjects: 30
Study 23731684 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP determined by Cst
Number of subjects: 30
Study 23731684 — intervention group
Group type: COMPARATOR
Intervention: PEEP titration with the four strategies
Number of subjects: 30
Study 20521648 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant NDV expressing H9 AIV hemagglutinin (HA), administered as a single dose of 10^6 50% egg infectious dose intranasally.
Number of subjects: 1
Study 20521648 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant NDV expressing H9 AIV hemagglutinin (HA)
Number of subjects: 1
Study 18447931 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO (Extracorporeal Membrane Oxygenation)
Number of subjects: 0
Study 18447931 — intervention group
Group type: COMPARATOR
Intervention: Conventional intensive care management
Number of subjects: 0
Study 17064590 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer (PCa) tissue
Number of subjects: 110
Study 12712102 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates with NE with IHE
Number of subjects: 83
Study 12712102 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonates with NE without IHE
Number of subjects: 83
Study 12712102 — intervention group
Group type: COMPARATOR
Intervention: Controls (neonates without complications)
Number of subjects: 83
Study 12964321 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour treatment with self-adhesive hydroactive polyurethane dressing (Cutinova thin)
Number of subjects: 0
Study 12964321 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour treatment with self-adhesive hydroactive polyurethane dressing (Cutinova thin)
Number of subjects: 0
Study 9461709 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with advanced renal insufficiency (serum creatinine levels above 265.3 mumol/l)
Number of subjects: 46
Study 9461709 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with mild renal failure (serum creatinine levels below 265.3 mumol/l)
Number of subjects: 46
Study 9461709 — intervention group
Group type: COMPARATOR
Intervention: Control group (27 healthy age-matched subjects)
Number of subjects: 46
Study 7948237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal vancomycin plus oral rifampin
Number of subjects: 126
Study 7948237 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trimethoprim/sulfamethoxazole (TMP/SMX)
Number of subjects: 126
Study 7948237 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin and ciprofloxacin
Number of subjects: 126
Study 7948237 — intervention group
Group type: EXPERIMENTAL
Intervention: Purulent exit-site discharge
Number of subjects: 126
Study 7948237 — intervention group
Group type: EXPERIMENTAL
Intervention: Exit-site tenderness or swelling
Number of subjects: 126
Study 3259681 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole immunotherapy
Number of subjects: 0
Study 3259681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3259681 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy controls
Number of subjects: 0
Study 31488496 — intervention group
Group type: EXPERIMENTAL
Intervention: Australian-validated mobile health (mHealth) platform for cardiac rehabilitation
Number of subjects: 0
Study 31488496 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 28134672 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing students with frequent training
Number of subjects: 20
Study 28134672 — intervention group
Group type: COMPARATOR
Intervention: Observers with 1-9 years experience
Number of subjects: 20
Study 28134672 — intervention group
Group type: COMPARATOR
Intervention: Observers with ≥10 years experience
Number of subjects: 20
Study 28134672 — intervention group
Group type: COMPARATOR
Intervention: Observers without any medical background
Number of subjects: 20
Study 25092513 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced cognitive-behavioral intervention (EI)
Number of subjects: 296
Study 25092513 — intervention group
Group type: COMPARATOR
Intervention: Minimal educational intervention (MI)
Number of subjects: 296
Study 23545360 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine histological assessment
Number of subjects: 310
Study 23545360 — intervention group
Group type: COMPARATOR
Intervention: Central review
Number of subjects: 310
Study 21794843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab-treated eyes undergoing cataract surgery
Number of subjects: 758
Study 21794843 — intervention group
Group type: EXPERIMENTAL
Intervention: Fellow eyes of ranibizumab-treated patients undergoing cataract surgery
Number of subjects: 758
Study 21794843 — intervention group
Group type: COMPARATOR
Intervention: Non-ranibizumab patients undergoing cataract surgery
Number of subjects: 758
Study 19488999 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus 1-alpha-hydroxyvitamin D3 (1-alpha(OH)D3; 0.5 microg per day)
Number of subjects: 35
Study 19488999 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 35
Study 16688412 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan (6.25 to 12.5 mg)
Number of subjects: 15
Study 15305946 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone (400 microg/day)
Number of subjects: 256
Study 15305946 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 256
Study 15305946 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 256
Study 15305946 — intervention group
Group type: EXPERIMENTAL
Intervention: All three drugs (Triamcinolone, Montelukast, Nedocromil)
Number of subjects: 256
Study 15305946 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone vs Nedocromil
Number of subjects: 256
Study 15305946 — intervention group
Group type: COMPARATOR
Intervention: Montelukast vs Nedocromil
Number of subjects: 256
Study 15305946 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone vs Montelukast
Number of subjects: 256
Study 11404533 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine combined with nelfinavir and two NRTIs
Number of subjects: 56
Study 11404533 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study 9199951 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative Coronary Angiography (QCA)
Number of subjects: 49
Study 9199951 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D Intracoronary Ultrasound (ICUS)
Number of subjects: 49
Study 9199951 — intervention group
Group type: COMPARATOR
Intervention: QCA
Number of subjects: 49
Study 8217174 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose and lactated Ringer's solution
Number of subjects: 33
Study 8217174 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusions
Number of subjects: 33
Study 31368121 — intervention group
Group type: EXPERIMENTAL
Intervention: Single implant mandibular overdenture (SIO)
Number of subjects: 22
Study 31368121 — intervention group
Group type: COMPARATOR
Intervention: Conventional complete denture (CD)
Number of subjects: 22
Study 30567497 — intervention group
Group type: COMPARATOR
Intervention: Standard care without checklist (control group)
Number of subjects: 119
Study 26851734 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out condition (N=61): Participants received an e-mail with a pre-scheduled appointment for influenza vaccination.
Number of subjects: 122
Study 26851734 — intervention group
Group type: COMPARATOR
Intervention: Opt-in condition (N=61): Participants received an e-mail explaining that they had to schedule an appointment if they wanted to get vaccinated.
Number of subjects: 122
Study 24827469 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (twice weekly for 6 weeks)
Number of subjects: 100
Study 24827469 — intervention group
Group type: COMPARATOR
Intervention: Control group (acupuncture started 6 weeks after enrollment)
Number of subjects: 100
Study 23055497 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavering wolf display (wolf chasing with changing intentions)
Number of subjects: 0
Study 23055497 — intervention group
Group type: COMPARATOR
Intervention: Wolf chasing with a single unchanging intention
Number of subjects: 0
Study 23055497 — intervention group
Group type: COMPARATOR
Intervention: Similar patterns of motion that are not perceived as goal-directed
Number of subjects: 0
Study 23055497 — intervention group
Group type: COMPARATOR
Intervention: Abrupt onsets and offsets of moving objects
Number of subjects: 0
Study 21198566 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS with PM
Number of subjects: 164
Study 21198566 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS without PM
Number of subjects: 164
Study 21198566 — intervention group
Group type: COMPARATOR
Intervention: Sham with PM
Number of subjects: 164
Study 17931620 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/day
Number of subjects: 80
Study 17931620 — intervention group
Group type: COMPARATOR
Intervention: therapeutic lifestyle changes intervention
Number of subjects: 80
Study 16003267 — intervention group
Group type: EXPERIMENTAL
Intervention: Preload reduction with Valsalva maneuver (nonstandardized and standardized) and sublingual nitroglycerin
Number of subjects: 45
Study 16003267 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary venous Doppler
Number of subjects: 45
Study 16003267 — intervention group
Group type: COMPARATOR
Intervention: Standardized Valsalva or pharmacologic preload reduction
Number of subjects: 45